NeuroPace forecasts 2026 revenue USD 99.5 million-101.5 million

• Neuropace forecast 2026 revenue of $99.5 million to $101.5 million, targeting 21%-23% RNS revenue growth.
• Non-GAAP gross margin outlook of 82%-83%.
• Non-GAAP operating expense guidance of $90 million to $92 million.
• Adjusted EBITDA expected at a loss of $7.5 million to $8.5 million.
• Forecast follows Q2 2026 RNS revenue of $22.5 million, up 21% year over year, with adjusted gross margin of 83.4%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.